Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06801626 · ClinicalTrials.gov registry record · Phase 3
Novel Strategies for Reducing Burn Scar Itch
A Phase 3 study of Wound and Burn Scar, sponsored by The University of Texas Medical Branch, Galveston.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 44
- Enrollment target
- 1
- Study location
NCT06801626 is a Phase 3 study of Wound and Burn Scar that is actively recruiting participants, run by The University of Texas Medical Branch, Galveston. The registered enrollment target is 44 participants, below the 420-participant average among 8 other Wound trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06801626, a Phase 3 study of Wound and Burn Scar, is actively recruiting participants, sponsored by The University of Texas Medical Branch, Galveston.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 44 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to see whether using diphenhydramine (Benadryl), famotidine (Pepcid), and cromolyn sodium will decrease burn scar itch.
Conditions Studied
Interventions
- OTHER Placebo
- COMBINATION_PRODUCT Famotidine and 4% topical cromolyn sodium
Study Locations (1)
Texas
- University of Texas Medical Branch, Galveston - Galveston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2025-03-01 |
| Est. Completion | 2027-11-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06801626
The ClinicalTrials.gov registry entry for NCT06801626 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 420-participant average among 8 other Wound trials with a reported enrollment target (90% lower). The listed sponsor is The University of Texas Medical Branch, Galveston, which has 203 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Wound appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06801626 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT06801626 about?
NCT06801626 is a clinical study titled "Novel Strategies for Reducing Burn Scar Itch". The purpose of the study is to see whether using diphenhydramine (Benadryl), famotidine (Pepcid), and cromolyn sodium will decrease burn scar itch.
What is the current status of trial NCT06801626?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 44 participants. The study started on 2025-03-01. Estimated completion is 2027-11-01.
What conditions does trial NCT06801626 study?
This clinical trial studies the following conditions: Wound, Burn Scar, Itch Scarring.
What interventions are being tested in trial NCT06801626?
The interventions under investigation include: Placebo (OTHER), Famotidine and 4% topical cromolyn sodium (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT06801626?
This trial is sponsored by The University of Texas Medical Branch, Galveston, which has 203 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06801626 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Wound
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Tissue Repair Gel in Venous Leg Ulcers in AU/US
RECRUITING · Phase 3
-
A Study to Evaluate ENERGI-F703 GEL in Diabetic Foot Ulcer
RECRUITING · Phase 3
-
Miro3D Randomized Controlled Trial (RCT)
RECRUITING · NA
-
A Study Evaluating the Safety and Efficacy of the 3M™ V.A.C. Peel and Place Dressing
RECRUITING · NA
-
Wound Healing Endpoint and Recurrence
ACTIVE NOT RECRUITING · Phase 1
-
Geko™ Cross Therapy Registry - Wound
ACTIVE NOT RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.